Aligos Therapeutics (NASDAQ:ALGS) Receives "Buy" Rating from HC Wainwright

Key Points

• Aligos Therapeutics (NASDAQ:ALGS) has received a "buy" rating from HC Wainwright, with a target price of $50.00, indicating a potential upside of 388.76% from its current trading price.
• The company reported a quarterly earnings per share (EPS) of ($1.53), surpassing analysts’ expectations by $0.82, and had revenues of $0.97 million for the quarter.
• Institutional investors own over 60% of Aligos Therapeutics, with significant stake increases from Tower Research Capital and Golden State Wealth Management recently reported.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report)'s stock had its "buy" rating restated by HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $50.00 target price on the stock. HC Wainwright's price objective suggests a potential upside of 388.76% from the stock's current price.

Aligos Therapeutics Stock Performance

Shares of NASDAQ ALGS traded down $0.65 during midday trading on Friday, reaching $10.23. 19,106 shares of the company traded hands, compared to its average volume of 161,254. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $46.80. The firm has a market cap of $62.91 million, a PE ratio of -0.52 and a beta of 2.79. The stock's 50-day simple moving average is $9.09 and its 200-day simple moving average is $8.16.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.35) by $0.82. The firm had revenue of $0.97 million for the quarter, compared to analysts' expectations of $0.43 million. Aligos Therapeutics had a negative net margin of 2,337.24% and a negative return on equity of 22.41%. On average, equities research analysts expect that Aligos Therapeutics will post -10.36 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALGS. Tower Research Capital LLC TRC increased its stake in shares of Aligos Therapeutics by 2,073.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 652 shares of the company's stock valued at $26,000 after acquiring an additional 622 shares during the last quarter. Golden State Wealth Management LLC grew its holdings in Aligos Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company's stock valued at $44,000 after purchasing an additional 2,674 shares during the period. XTX Topco Ltd bought a new stake in Aligos Therapeutics in the second quarter valued at approximately $100,000. AlphaQuest LLC bought a new stake in Aligos Therapeutics in the first quarter valued at approximately $130,000. Finally, Northern Trust Corp acquired a new stake in Aligos Therapeutics in the fourth quarter worth $205,000. Institutional investors own 60.43% of the company's stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.